Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 4 | BMC Cancer

Fig. 4

From: NPM1 as a potential therapeutic target for atypical teratoid/rhabdoid tumors

Fig. 4

The effects of NSC348884 on multiple AT/RT cell lines. a A significant decrease in cell viability was observed at 48 h in all 7 AT/RT cell lines tested. The half maximal inhibitory concentration (IC50) ranges from 4.8 to 9.1 μM. b In the BrdU labeling assay, cell proliferation was also suppressed by NSC348884 at 10 μM in 72 h. c Western blot shows that NPM1 protein expression is effectively suppressed at IC50 doses of NSC348884 for each cell line. Cropped gel images are displayed for clarification

Back to article page